Cancer Treatment Today

Surgical cure for prostate cancer can be expected only if the entire tumor is excised, and in men with clinical stage T1 or T2 prostate cancer, 50% have tumor extension outside the prostatic capsule and 40% have positive surgical margins.
Some of these patients have incompletely resected cancer and, therefore, are at an increased risk for local recurrence and progression. In addition, despite considerable advances in prostate cancer research, high-risk, localized prostate cancer remains an extremely refractory disease. Single-modality treatment offers a 5-year, biochemical, disease-free survival rate of no better than 50%.
Most trials have used 3 months of NAD therapy and have demonstrated a significant decrease in prostate volume by 20-50% and in serum prostate-specific antigen (PSA) levels by more than 90%. A significant increase in organ-confined disease and a decrease in the incidence of positive margins have also been reported.
However, no randomized or nonrandomized study using 3 months of neoadjuvant therapy has shown any statistically significant benefit in terms of overall and disease-free survival. Some preliminary results show that increasing the duration of therapy to 6 or 8 months further reduces tumor volume and PSA nadir levels and decreases the likelihood of positive margins. Moreover, it is possible that a subset of patients is likely to benefit from neoadjuvant therapy; this population of patients has yet to be defined, but its parameters may become clearer as the optimal duration and form of ADT therapy is defined.

However it does not use the standard or level of service is most appropriate… . It is experimental investigational and not commonly and customarily recognized by the medical profession and is not appropriate and generally accepted. It is not approved by the FDA or CMS.

Hendrik Paul Van PoppelHendrik Neoadjuvant and Adjuvant Hormone Therapy: How and When?
December 2008 European Urology Supplements 7(13):747-751

Yasuyoshi Miyata Yuichiro Nakamura Takuji Yasuda Tomohiro Matsuo Kojiro Ohba Bungo Furusato Junya Fukuoka Hideki Sakai, Neoadjuvant hormonal therapy for low‐risk prostate cancer induces biochemical recurrence after radical prostatectomy via increased lymphangiogenesis‐related parameters Prostate 28 August 2017